Merck & Company (MRK) 60.49 $MRK
5 Things Gilead Sciences, Inc. Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 10:30AM CDT
Gilead Sciences presented at the Morgan Stanley Healthcare Conference last week. Rather than the standard presentation of a slide deck, the conference is more of a Q&A, which produces off-the-cuff responses that can be more enlightening for...
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Fri Sep 19, 10:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, is teaming with celebrity chef and cookbook author Leticia Moreinos Schwartz on Desafiando La Diabetes: Logra Tus Metas, an educational program encouraging Hispanics with type 2 diabetes to achieve better control of their blood sugar -- a key treatment goal to help reduce the risk of serious health problems. Hispanics in the United States are at a higher risk for developing type 2 diabetes than non-Hispanic white adults, and it is the fifth leading cause of death within the Hispanic community. Chef Leticia, who has a family history of type 2 diabetes, will visit select cities to cook up some of her favorite diabetes-friendly Latin recipes, urge Hispanics to know their A1C (average blood sugar level over the past two to three months), and work with their doctors to set and attain their own A1C goal.
Dow 30 Stock Roundup: Boeing to Receive $4.2B Contract from NASA, Cisco to Acquire Metacloud - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Sep 19, 9:40AM CDT
The Dow had a largely positive week after the Fed hinted that there would be no sooner-than-expected rate hike.
Singulair Asthma Market to 2023 - Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com
PRWeb - Fri Sep 19, 9:31AM CDT
Singulair, developed by Merck, is a CysLT1 receptor inhibitor, blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs to the family of Cys-LTs, which are mediators released from a variety of cells, including mast cells and eosinophils, and which bind to the family of CysLT receptors. Several studies have determined that there are higher concentrations of Cys-LTs in the airways and urine of asthmatics compared with non-asthmatic individuals. The production of CysLTs is increased in asthmatics, particularly during the early phase of bronchoconstriction that follows allergen challenge. Cys-LT signaling results in airway edema, smooth muscle contraction, and aberrant immune cell activity.
Merck (MRK) Crosses Pivot Point Resistance at $60.49
Comtex SmarTrend(R) - Fri Sep 19, 9:28AM CDT
Merck (NYSE:MRK) has opened bullishly above the pivot of $60.16 today and has reached the first level of resistance at $60.49. Investors may be interested in a cross of the next upside pivot targets of $60.68 and $61.20.
Stock Market News for September 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 9:10AM CDT
Benchmarks settled in the green on Thursday a day after Fed’s pledge to keep short-term interest rates near zero for a “considerable time”
Merck (MRK) On Momo Momentum Watch Today
at The Street - Fri Sep 19, 8:49AM CDT
Trade-Ideas LLC identified Merck (MRK) as a momo momentum candidate
Neogen signs Igenity Dairy Heifer Programme marketing agreement with Merck Animal Health
M2 - Fri Sep 19, 6:06AM CDT
Animal safety company Neogen (NasdaqGS:NEOG) said on Thursday that it has signed a strategic agreement to market its Igenity Dairy Heifer Programme through Merck Animal Health.
Merck Serono Awards Grant for Growth Innovation (GGI) for the First Time
PR Newswire Europe - Fri Sep 19, 3:50AM CDT
DARMSTADT, Germany, September 19, 2014 /PRNewswire/ --
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Merck Strengthens Executive Board
PR Newswire Europe - Thu Sep 18, 10:14AM CDT
DARMSTADT, Germany, September 18, 2014 /PRNewswire/ --
Merck Animal Health to market Neogen's dairy genomic program
PR Newswire - Thu Sep 18, 7:45AM CDT
Neogen Corporation (Nasdaq: NEOG) announced today that it has entered into a strategic agreement with Merck Animal Health to market Neogen's Igenity® Dairy Heifer Program.
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
Global Veterinary Diagnostics Market - By Products, By Animal Types & Geography - Trends & Forecasts - 2014-2019
M2 - Thu Sep 18, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rdptvj/global_veterinary) has announced the addition of the "Global Veterinary Diagnostics Market - By Products, By Animal Types & Geography - Trends & Forecasts- 2014-2019" report to their offering. The global market for diagnostics in veterinary healthcare is valued at an estimated $1.59 billion in 2014 Ever-rising demand for animal protein and stricter regulations concerning food safety will propel the market for diagnostics in animal healthcare to grow at a healthy CAGR of 4.6 % to reach a market size of $2.02 billion by 2019. Diagnostics provide tools for effective and rapid testing to undertake preventative or remedial measures for the health of the animal population. For instance, lateral flow and other rapid tests are used in veterinary medicine to test commercial livestock (large animals - cows, poultry, sheep, pigs, etc.) and household pets (cats, dogs, etc.) to test for the presence of a variety of medical conditions caused by bacteria, viruses, allergies, fertility issues and diabetes. Developing regions in Asia-pacific and Africa are expected to form a new revenue pocket in the market, with India, China and Brazil constituting a majority of market growth over the next decade. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4.Global Veterinary Diagnostic Market Segmentation 5. Competitive landscape 6. Company profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/rd...veterinary
Global Farm Animal Healthcare Market 2014-2019 - Products, Diagnostic Technologies & Animal Type Analysis of the $20 Billion Industry
M2 - Thu Sep 18, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/prwmjn/farm_animal) has announced the addition of the "Farm Animal Healthcare Market By Products (Vaccines, Paraciticides, Anti-Infectives, Medicinal Feed Additives, And Other Pharmaceuticals), By Diagnostic Technologies, By Animal Type (Cattle, Sheep, Pigs, Poultry, Fish), By Geography - Trends And Fore" report to their offering. The market for animal healthcare for farm animals is estimated to be worth $13.46 billion in 2014. Expected to grow at a CAGR of 8.25%, the market is set to reach $20.2 billion by 2018 The farm animal health market is segmented based on type of products (Vaccines, Paraciticides, Anti-infectives, Medicinal feed additives, and other pharmaceuticals), based on diagnostics (Enzyme Linked Immuno sorbent assay(ELISA), Rapid Immuno Migration( RIM)) and based on genetics. By geography, the market is divided into North America, Asia-Pacific, Europe and Rest of World. Europe accounts for the largest share of the animal vaccines market, followed by North America. The developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors in the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Farm Animal Market Segmentation - By products 5. Global Farm Animal Diagnostics Market 6. Global Farm Animal Genetics Market 7. Global Farm Animal Market Segmentation - By Geography 8. Competitive landscape 9. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/pr...arm_animal
Global Veterinary Paraciticides Market 2014-2019: Segmented By Disease Causing Organisms, Products & Animal Types
M2 - Thu Sep 18, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/flbfl5/global_veterinary) has announced the addition of the "Global Veterinary Paraciticides Market Segmented By Disease Causing Organisms, By Products, By Animal Types & By Geography - Trends & Forecasts 2014- 2019" report to their offering. The global market for paraciticides in veterinary healthcare is estimated to be worth $2.89 billion in 2014. Expected to grow at a CAGR of 6.0%, the market is set to reach US$ 3.97 billion by 2019. Veterinary pharmaceuticals, including parasiticides, have transformed the health of companion and livestock animals across the globe over the past two decades. Today, the spectrum of parasiticides for veterinary applications continues to expand with a variety of ectoparasiticides, endoparasiticides, and endectocides being launched every year. Constant innovationis leading to the emergence of novel parasiticide delivery systems as well. However, stringent regulations and norms are the major constraints for market growth, with some countries not allowing the use of paraciticides on food-producing animals. This report provides an extensive coverage of the market: By disease-causing organisms - Ectoparaciticides (Fleas, Lice, Mice) and Endoparaciticides (Gastrointestinal, nematode, heartworms,Lungworms); By species within companion and farm animals;By geography - North America, Asia-Pacific, Europe and the rest of world. A majority of the growth in the market is expected to be from the emerging markets in the Asia-Pacific and Latin American regions. Key Topics Covered: 1. Intoduction 2. Market Analysis 3. Market Dynamics 4.Global veterinary paraciticides market Segmentation 5. Competitive landscape 6. Company profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/fl...veterinary
Global Veterinary Medicinal Market Report 2014-2019 - Key Analysis of the $2 Billion Industry
M2 - Thu Sep 18, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cn2b2h/global_veterinary) has announced the addition of the "Global Veterinary Medicinal Feed Additives Market Segmented By Products, By Livestock & By Geography - Trends & Forecasts 2014-2019" report to their offering. The Global Veterinary Medicinal feed additives market is estimated at $1.59 billion in 2014. Increasing consumption of meat and dairy products across the globe is expected to propel the market at a CAGR of 4.6 % to reach $2.02 billion by 2019 Epidemics such as bird flu, other diseases such as foot-and mouth-disease, and environmental concerns have led to increased concern over animal health around the globe, due to which, meat producers have increased their focus on feed quality and certification. Typical feed additives include vitamins, trace elements, preservatives, anti-oxidants, etc. Increasing Zoonotic and water borne diseases in animals are a triggering factor for growth in this market. North America and Asia-Pacific are the top two consumers of feed additives in the world, together accounting for more than 60% of the consumption. Asia-Pacific is estimated to be the fastest growing region for medicinal feed additives in terms of revenue. Growth is particularly high in emerging countries such as China, India, and Brazil, because of increasing income levels and rising per capita meat consumption. The restraints of the market are, increasing raw material cost and regulatory structure. This report provides an exhaustive coverage of the market through different categorizations. By type of product - Antibiotics, Vitamins, Antioxidants, Amino Acids, Feed Enzymes, Acidifiers, Prebiotics & Probiotics, Minerals, and Others; By live stock - Swine, Poultry, Cattle, Aquaculture and others Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Veterinary Medicinal Feed Additives Market Segmentation 6. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/cn...veterinary
Companion Animal Health Market 2014-2019 - Opportunities & Forecasts for the $13 Billion Industry
M2 - Thu Sep 18, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wdsnh6/_companion_animal) has announced the addition of the " Companion Animal Health Market By Products, By Diagnostic Technologies, By Animals Type, By Geography-Trends And Forecast (2014-2019)" report to their offering. The global market for companion animal healthcare is valued at $8.5 billion in 2013. Expected to grow at a CAGR of 7.86%, the market is set to reach $13.37 billion by 2019 The companion animal health market is segmented based on type of products i. e Vaccines, Paraciticides, Anti-infectives, Medicinal feed additives, and other pharmaceuticals, based on diagnostics i.e Enzyme Linked Immuno sorbent assay(ELISA), Rapid Immuno Migration( RIM), based on genetics,based on geography market is divided into North America, Asia-Pacific, Europe and Rest of World. Europe accounts for the largest share of the animal vaccines market, followed by North America. The developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors in the market. Scope of the Report Products - Vaccines - Paraciticides - Anti-Infectives - Medicinal Feed Additive - Other Pharmaceuticals Diagnostic Technologies Animals Type - Dogs - Cats - Horses Key Topics Covered: 1.Introduction 2. Market Analysis 3. Market Dynamics 4.Market Segmentation 5. Global Companion Animal Diagnostics Market 6. Global Companion Animal Genetics Market 7. Global Companion Market Segmentation, By Geography 8. Competitive landscape 9. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/wd...ion_animal
Global Veterinary Vaccines Market 2014-2019 - Key Analysis of the $12 Billion Industry
M2 - Thu Sep 18, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrcznt/global_veterinary) has announced the addition of the "Global Veterinary Vaccines Market Segmented By Veterinary Diseases , By Technology, By Animal Type & By Geography - Trends And Forecast 2014-2019" report to their offering. The global market for veterinary vaccines is estimated to be worth $12.0 billion in 2014 and is expected to grow at a CAGR of 8.8 %, the market is set to reach a value of US$19 billion by 2019 The global veterinary vaccine market is segmented based on type of disease in companion and farm animals - poultry vaccines (Bronchitis, Avian Influenza, Marek's disease, New castle disease), Swine vaccines (Porcine reproductive disease, Swine influenza, Swine Pneumonia). Based on vaccine technology, the market is segmented into toxoid vaccines, recombinant vaccines, Inactivated vaccines and Live attenuated vaccines. Based on geography, the market is divided into North America, Asia-Pacific, Europe and the rest of world. Europe accounts for the largest share of the animal vaccines market, followed by North America. Developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors to the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global veterinary vaccine market Segmentation, By Type of Animals,based on diseases 5. Competitive landscape 6. Company profiles 7. Appendix Companies Featured: - Zoetis Animal Healthcare - Merck - Merial (Animal Health Division Of Sanofi) - Elanco - Bayer Healthcare - Novartis Animal Health, Inc. - Virbac - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/rr...veterinary
Asia-Pacific Veterinary Healthcare Market 2014-2020 - Products, Veterinary Diagnostic Technologies, Veterinary Genetics & By Animal Types
M2 - Thu Sep 18, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlpr25/asiapacific) has announced the addition of the "Asia-Pacific Veterinary Healthcare Market Segmented By Products, Veterinary Diagnostic Technologies, Veterinary Genetics, By Animal Types - Trends & Forecasts 2014-2019" report to their offering. The Veterinary healthcare market in the Asia-Pacific region is estimated to increase at a CAGR of 8.97% to reach $2.52 billion by 2019 Better standards of living have resulted in an increase in pet ownership and livestock product consumption across the Asia Pacific region. With more pet owners willing to pay for veterinary care, the demand for supplements and other treatment options for companion animals is on the rise. Increasing consumer concern for where and how their food is produced is leading to a tougher scrutiny of feeding and rearing practices of farm animals. All the same, increased competition for cultivated land and scarcity of arable land could affect the animal healthcare market in terms of demand from livestock production. This report provides an exhaustive coverage of the market with multi-level segmentation focusing on animal species (farm animals and companion animals), type of healthcare products (vaccines, paraciticides, anti-infectives, medicinal feed additives, and other pharmaceuticals) and by geography. Regional coverage includes a study of the animal healthcare markets in India, China, Japan. Demand for Veterinary healthcare products and services in Japan is currently the largest of all countries in Asia-Pacific. However, Japan is slated to lose its leader status due heavy regulation requiringrigorous testing - much of it unnecessary. The market for Veterinary pharmaceuticals and biological products in Asia-Pacific has seen scant growth for many years, generally around 1.5%, while global growth has generally been in the 3-4% range. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Animal Types, Based On Products 5. Asia-Pacific Veterinary Diagnostics Market 6. Asia-Pacific Veterinary Genetics Market 7.Animal Species 8. Country Level Analysis 9. Competitive Landscape 10. Company Profiles - Bayer Healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/ql...siapacific
5 Things Gilead Sciences, Inc. Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 10:30AM CDT
Gilead Sciences presented at the Morgan Stanley Healthcare Conference last week. Rather than the standard presentation of a slide deck, the conference is more of a Q&A, which produces off-the-cuff responses that can be more enlightening for...
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Fri Sep 19, 10:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, is teaming with celebrity chef and cookbook author Leticia Moreinos Schwartz on Desafiando La Diabetes: Logra Tus Metas, an educational program encouraging Hispanics with type 2 diabetes to achieve better control of their blood sugar -- a key treatment goal to help reduce the risk of serious health problems. Hispanics in the United States are at a higher risk for developing type 2 diabetes than non-Hispanic white adults, and it is the fifth leading cause of death within the Hispanic community. Chef Leticia, who has a family history of type 2 diabetes, will visit select cities to cook up some of her favorite diabetes-friendly Latin recipes, urge Hispanics to know their A1C (average blood sugar level over the past two to three months), and work with their doctors to set and attain their own A1C goal.
Dow 30 Stock Roundup: Boeing to Receive $4.2B Contract from NASA, Cisco to Acquire Metacloud - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Sep 19, 9:40AM CDT
The Dow had a largely positive week after the Fed hinted that there would be no sooner-than-expected rate hike.
Singulair Asthma Market to 2023 - Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com
PRWeb - Fri Sep 19, 9:31AM CDT
Singulair, developed by Merck, is a CysLT1 receptor inhibitor, blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs to the family of Cys-LTs, which are mediators released from a variety of cells, including mast cells and eosinophils, and which bind to the family of CysLT receptors. Several studies have determined that there are higher concentrations of Cys-LTs in the airways and urine of asthmatics compared with non-asthmatic individuals. The production of CysLTs is increased in asthmatics, particularly during the early phase of bronchoconstriction that follows allergen challenge. Cys-LT signaling results in airway edema, smooth muscle contraction, and aberrant immune cell activity.
Merck (MRK) Crosses Pivot Point Resistance at $60.49
Comtex SmarTrend(R) - Fri Sep 19, 9:28AM CDT
Merck (NYSE:MRK) has opened bullishly above the pivot of $60.16 today and has reached the first level of resistance at $60.49. Investors may be interested in a cross of the next upside pivot targets of $60.68 and $61.20.
Stock Market News for September 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 9:10AM CDT
Benchmarks settled in the green on Thursday a day after Fed’s pledge to keep short-term interest rates near zero for a “considerable time”
Merck (MRK) On Momo Momentum Watch Today
at The Street - Fri Sep 19, 8:49AM CDT
Trade-Ideas LLC identified Merck (MRK) as a momo momentum candidate
Neogen signs Igenity Dairy Heifer Programme marketing agreement with Merck Animal Health
M2 - Fri Sep 19, 6:06AM CDT
Animal safety company Neogen (NasdaqGS:NEOG) said on Thursday that it has signed a strategic agreement to market its Igenity Dairy Heifer Programme through Merck Animal Health.
Merck Serono Awards Grant for Growth Innovation (GGI) for the First Time
PR Newswire Europe - Fri Sep 19, 3:50AM CDT
DARMSTADT, Germany, September 19, 2014 /PRNewswire/ --
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Merck Strengthens Executive Board
PR Newswire Europe - Thu Sep 18, 10:14AM CDT
DARMSTADT, Germany, September 18, 2014 /PRNewswire/ --
Merck Animal Health to market Neogen's dairy genomic program
PR Newswire - Thu Sep 18, 7:45AM CDT
Neogen Corporation (Nasdaq: NEOG) announced today that it has entered into a strategic agreement with Merck Animal Health to market Neogen's Igenity® Dairy Heifer Program.
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
Global Veterinary Diagnostics Market - By Products, By Animal Types & Geography - Trends & Forecasts - 2014-2019
M2 - Thu Sep 18, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rdptvj/global_veterinary) has announced the addition of the "Global Veterinary Diagnostics Market - By Products, By Animal Types & Geography - Trends & Forecasts- 2014-2019" report to their offering. The global market for diagnostics in veterinary healthcare is valued at an estimated $1.59 billion in 2014 Ever-rising demand for animal protein and stricter regulations concerning food safety will propel the market for diagnostics in animal healthcare to grow at a healthy CAGR of 4.6 % to reach a market size of $2.02 billion by 2019. Diagnostics provide tools for effective and rapid testing to undertake preventative or remedial measures for the health of the animal population. For instance, lateral flow and other rapid tests are used in veterinary medicine to test commercial livestock (large animals - cows, poultry, sheep, pigs, etc.) and household pets (cats, dogs, etc.) to test for the presence of a variety of medical conditions caused by bacteria, viruses, allergies, fertility issues and diabetes. Developing regions in Asia-pacific and Africa are expected to form a new revenue pocket in the market, with India, China and Brazil constituting a majority of market growth over the next decade. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4.Global Veterinary Diagnostic Market Segmentation 5. Competitive landscape 6. Company profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/rd...veterinary
Global Farm Animal Healthcare Market 2014-2019 - Products, Diagnostic Technologies & Animal Type Analysis of the $20 Billion Industry
M2 - Thu Sep 18, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/prwmjn/farm_animal) has announced the addition of the "Farm Animal Healthcare Market By Products (Vaccines, Paraciticides, Anti-Infectives, Medicinal Feed Additives, And Other Pharmaceuticals), By Diagnostic Technologies, By Animal Type (Cattle, Sheep, Pigs, Poultry, Fish), By Geography - Trends And Fore" report to their offering. The market for animal healthcare for farm animals is estimated to be worth $13.46 billion in 2014. Expected to grow at a CAGR of 8.25%, the market is set to reach $20.2 billion by 2018 The farm animal health market is segmented based on type of products (Vaccines, Paraciticides, Anti-infectives, Medicinal feed additives, and other pharmaceuticals), based on diagnostics (Enzyme Linked Immuno sorbent assay(ELISA), Rapid Immuno Migration( RIM)) and based on genetics. By geography, the market is divided into North America, Asia-Pacific, Europe and Rest of World. Europe accounts for the largest share of the animal vaccines market, followed by North America. The developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors in the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Farm Animal Market Segmentation - By products 5. Global Farm Animal Diagnostics Market 6. Global Farm Animal Genetics Market 7. Global Farm Animal Market Segmentation - By Geography 8. Competitive landscape 9. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/pr...arm_animal
Global Veterinary Paraciticides Market 2014-2019: Segmented By Disease Causing Organisms, Products & Animal Types
M2 - Thu Sep 18, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/flbfl5/global_veterinary) has announced the addition of the "Global Veterinary Paraciticides Market Segmented By Disease Causing Organisms, By Products, By Animal Types & By Geography - Trends & Forecasts 2014- 2019" report to their offering. The global market for paraciticides in veterinary healthcare is estimated to be worth $2.89 billion in 2014. Expected to grow at a CAGR of 6.0%, the market is set to reach US$ 3.97 billion by 2019. Veterinary pharmaceuticals, including parasiticides, have transformed the health of companion and livestock animals across the globe over the past two decades. Today, the spectrum of parasiticides for veterinary applications continues to expand with a variety of ectoparasiticides, endoparasiticides, and endectocides being launched every year. Constant innovationis leading to the emergence of novel parasiticide delivery systems as well. However, stringent regulations and norms are the major constraints for market growth, with some countries not allowing the use of paraciticides on food-producing animals. This report provides an extensive coverage of the market: By disease-causing organisms - Ectoparaciticides (Fleas, Lice, Mice) and Endoparaciticides (Gastrointestinal, nematode, heartworms,Lungworms); By species within companion and farm animals;By geography - North America, Asia-Pacific, Europe and the rest of world. A majority of the growth in the market is expected to be from the emerging markets in the Asia-Pacific and Latin American regions. Key Topics Covered: 1. Intoduction 2. Market Analysis 3. Market Dynamics 4.Global veterinary paraciticides market Segmentation 5. Competitive landscape 6. Company profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/fl...veterinary
Global Veterinary Medicinal Market Report 2014-2019 - Key Analysis of the $2 Billion Industry
M2 - Thu Sep 18, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cn2b2h/global_veterinary) has announced the addition of the "Global Veterinary Medicinal Feed Additives Market Segmented By Products, By Livestock & By Geography - Trends & Forecasts 2014-2019" report to their offering. The Global Veterinary Medicinal feed additives market is estimated at $1.59 billion in 2014. Increasing consumption of meat and dairy products across the globe is expected to propel the market at a CAGR of 4.6 % to reach $2.02 billion by 2019 Epidemics such as bird flu, other diseases such as foot-and mouth-disease, and environmental concerns have led to increased concern over animal health around the globe, due to which, meat producers have increased their focus on feed quality and certification. Typical feed additives include vitamins, trace elements, preservatives, anti-oxidants, etc. Increasing Zoonotic and water borne diseases in animals are a triggering factor for growth in this market. North America and Asia-Pacific are the top two consumers of feed additives in the world, together accounting for more than 60% of the consumption. Asia-Pacific is estimated to be the fastest growing region for medicinal feed additives in terms of revenue. Growth is particularly high in emerging countries such as China, India, and Brazil, because of increasing income levels and rising per capita meat consumption. The restraints of the market are, increasing raw material cost and regulatory structure. This report provides an exhaustive coverage of the market through different categorizations. By type of product - Antibiotics, Vitamins, Antioxidants, Amino Acids, Feed Enzymes, Acidifiers, Prebiotics & Probiotics, Minerals, and Others; By live stock - Swine, Poultry, Cattle, Aquaculture and others Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Veterinary Medicinal Feed Additives Market Segmentation 6. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/cn...veterinary
Companion Animal Health Market 2014-2019 - Opportunities & Forecasts for the $13 Billion Industry
M2 - Thu Sep 18, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wdsnh6/_companion_animal) has announced the addition of the " Companion Animal Health Market By Products, By Diagnostic Technologies, By Animals Type, By Geography-Trends And Forecast (2014-2019)" report to their offering. The global market for companion animal healthcare is valued at $8.5 billion in 2013. Expected to grow at a CAGR of 7.86%, the market is set to reach $13.37 billion by 2019 The companion animal health market is segmented based on type of products i. e Vaccines, Paraciticides, Anti-infectives, Medicinal feed additives, and other pharmaceuticals, based on diagnostics i.e Enzyme Linked Immuno sorbent assay(ELISA), Rapid Immuno Migration( RIM), based on genetics,based on geography market is divided into North America, Asia-Pacific, Europe and Rest of World. Europe accounts for the largest share of the animal vaccines market, followed by North America. The developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors in the market. Scope of the Report Products - Vaccines - Paraciticides - Anti-Infectives - Medicinal Feed Additive - Other Pharmaceuticals Diagnostic Technologies Animals Type - Dogs - Cats - Horses Key Topics Covered: 1.Introduction 2. Market Analysis 3. Market Dynamics 4.Market Segmentation 5. Global Companion Animal Diagnostics Market 6. Global Companion Animal Genetics Market 7. Global Companion Market Segmentation, By Geography 8. Competitive landscape 9. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/wd...ion_animal
Global Veterinary Vaccines Market 2014-2019 - Key Analysis of the $12 Billion Industry
M2 - Thu Sep 18, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrcznt/global_veterinary) has announced the addition of the "Global Veterinary Vaccines Market Segmented By Veterinary Diseases , By Technology, By Animal Type & By Geography - Trends And Forecast 2014-2019" report to their offering. The global market for veterinary vaccines is estimated to be worth $12.0 billion in 2014 and is expected to grow at a CAGR of 8.8 %, the market is set to reach a value of US$19 billion by 2019 The global veterinary vaccine market is segmented based on type of disease in companion and farm animals - poultry vaccines (Bronchitis, Avian Influenza, Marek's disease, New castle disease), Swine vaccines (Porcine reproductive disease, Swine influenza, Swine Pneumonia). Based on vaccine technology, the market is segmented into toxoid vaccines, recombinant vaccines, Inactivated vaccines and Live attenuated vaccines. Based on geography, the market is divided into North America, Asia-Pacific, Europe and the rest of world. Europe accounts for the largest share of the animal vaccines market, followed by North America. Developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors to the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global veterinary vaccine market Segmentation, By Type of Animals,based on diseases 5. Competitive landscape 6. Company profiles 7. Appendix Companies Featured: - Zoetis Animal Healthcare - Merck - Merial (Animal Health Division Of Sanofi) - Elanco - Bayer Healthcare - Novartis Animal Health, Inc. - Virbac - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/rr...veterinary
Asia-Pacific Veterinary Healthcare Market 2014-2020 - Products, Veterinary Diagnostic Technologies, Veterinary Genetics & By Animal Types
M2 - Thu Sep 18, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlpr25/asiapacific) has announced the addition of the "Asia-Pacific Veterinary Healthcare Market Segmented By Products, Veterinary Diagnostic Technologies, Veterinary Genetics, By Animal Types - Trends & Forecasts 2014-2019" report to their offering. The Veterinary healthcare market in the Asia-Pacific region is estimated to increase at a CAGR of 8.97% to reach $2.52 billion by 2019 Better standards of living have resulted in an increase in pet ownership and livestock product consumption across the Asia Pacific region. With more pet owners willing to pay for veterinary care, the demand for supplements and other treatment options for companion animals is on the rise. Increasing consumer concern for where and how their food is produced is leading to a tougher scrutiny of feeding and rearing practices of farm animals. All the same, increased competition for cultivated land and scarcity of arable land could affect the animal healthcare market in terms of demand from livestock production. This report provides an exhaustive coverage of the market with multi-level segmentation focusing on animal species (farm animals and companion animals), type of healthcare products (vaccines, paraciticides, anti-infectives, medicinal feed additives, and other pharmaceuticals) and by geography. Regional coverage includes a study of the animal healthcare markets in India, China, Japan. Demand for Veterinary healthcare products and services in Japan is currently the largest of all countries in Asia-Pacific. However, Japan is slated to lose its leader status due heavy regulation requiringrigorous testing - much of it unnecessary. The market for Veterinary pharmaceuticals and biological products in Asia-Pacific has seen scant growth for many years, generally around 1.5%, while global growth has generally been in the 3-4% range. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Animal Types, Based On Products 5. Asia-Pacific Veterinary Diagnostics Market 6. Asia-Pacific Veterinary Genetics Market 7.Animal Species 8. Country Level Analysis 9. Competitive Landscape 10. Company Profiles - Bayer Healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/ql...siapacific
